Real-World Outcomes of Olaparib for Relapsed BRCA Ovarian Cancer Consistent with Previous Trials
With any new therapy or drug treatment there is a honeymoon period of great enthusiasm and hope. This can be exaggerated by the results of Clinical Trials, which may emphasise positive results and present them in a manner calculated to increase sales.
Fortunately scientific method assists to determine the true impact of trials by replication and confirmation. This article looks at a real-world study of 128 women with relapsed ovarian cancer who were treated with Olaparib as part of normal therapy and compared the outcomes with the published trial results (SOLO III).
The SOLO III trial examined the effect of Olaparib treatment for ovarian cancer patients who relapsed after initial chemo and surgery. Its main finding was an improved median Progress Free Survival (PFS) of 30 months compared to 5 months with placebo. For the real-world study the median PFS was 15.5 months.
Significant side effects were noted with almost 12% of the patients having to discontinue the treatment. The authors suggest the outcomes are consistent with the results of SOLO III.
No comments:
Post a Comment